Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Epidemiology and determinants of obesity in China784
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials651
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study400
Consensus on diagnosis and management of Cushing's disease: a guideline update400
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study366
Risks and burdens of incident diabetes in long COVID: a cohort study354
Obesity in children and adolescents: epidemiology, causes, assessment, and management340
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial322
Thyroid cancer incidence trends by histology in 25 countries: a population-based study309
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials306
A global view of the interplay between non-alcoholic fatty liver disease and diabetes288
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials271
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020270
Polycystic ovary syndrome250
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland242
Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study230
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement229
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group225
Health policy and public health implications of obesity in China224
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study214
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial191
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study190
Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records189
Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study187
Bone fragility in diabetes: novel concepts and clinical implications184
COVID-19 and metabolic disease: mechanisms and clinical management169
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial166
Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study159
Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating156
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England147
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes146
Management of diabetes and hyperglycaemia in the hospital145
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)143
RETRACTED: Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses143
Diagnosis and treatment of primary aldosteronism138
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 131
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial129
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial128
Clinical management and treatment of obesity in China127
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel123
Nutritional intake and bone health118
Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases117
Diabetes, metabolic disease, and telomere length114
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multic110
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care109
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial107
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial106
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial101
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial100
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality98
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial96
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings96
Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study95
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial94
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials94
Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction93
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada92
Menopause: a cardiometabolic transition87
Sexual dimorphism in COVID-19: potential clinical and public health implications85
Osteoporosis in men85
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy o84
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial82
Diagnosis of thyroid nodules82
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial81
Acromegaly: pathogenesis, diagnosis, and management80
Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study79
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 201979
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial78
Obesity in people living with type 1 diabetes74
Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria72
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study72
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK72
A worldwide journey of thyroid cancer incidence centred on tumour histology72
0.053693056106567